Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer

(Dana-Farber Cancer Institute) Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.